The cardiometabolic workup: when to go beyond the standard lipid panel
A standard lipid panel tells you how much cholesterol a patient carries. It does not tell you how many atherogenic particles are circulating, and that distinction is where a lot of cardiovascular risk hides. This is the workup for the patient whose standard panel looks acceptable but whose story says the risk picture is not complete. It builds on the metabolic baseline, the fasting insulin and HOMA-IR work, and extends it into the artery.
Start with the metabolic foundation
Before the advanced lipid markers, the cardiometabolic picture starts with the markers you already justified, fasting insulin, HOMA-IR, A1c, and the standard lipid panel including the triglyceride to HDL ratio. A rising triglyceride to HDL ratio is itself an early signal of insulin resistance and small dense LDL, and it often tells you the advanced workup is warranted before you order it.
ApoB, the single most useful addition
If you add one advanced marker, make it ApoB. Every atherogenic particle, LDL, VLDL remnants, IDL, and Lp(a), carries exactly one ApoB molecule, so ApoB counts the particles rather than the cholesterol they carry. This matters because of discordance, the patient whose LDL-C looks normal but whose ApoB is high, which means a high number of small, dense particles that a standard panel completely misses. That pattern is almost always driven by insulin resistance and elevated triglycerides, which is why this workup belongs to the metabolic patient. Functional and guideline targets converge here, under 100 for moderate risk, under 80 as a stronger goal, and under 65 for the high-risk patient.
Lp(a), the once-in-a-lifetime test
Lp(a) is roughly 90 percent genetically determined, so it is checked once in a lifetime, not tracked. Its value is explanatory, an elevated Lp(a), flagged at or above 50 mg/dL or about 125 nmol/L, can explain why a patient develops early cardiovascular disease despite an otherwise clean lipid picture or a strong family history that standard markers do not account for. It is a risk-enhancing factor that changes how aggressively you address everything else that is modifiable.
The inflammatory companion
hs-CRP earns its place alongside the advanced lipids, because particle burden becomes dangerous in the presence of arterial inflammation. An elevated ApoB or Lp(a) paired with an elevated hs-CRP is a meaningfully different risk picture than either alone.
A marker to hold loosely
LDL particle number by NMR or ion mobility is offered by the major labs and is an excellent predictor, but whether it adds substantially beyond ApoB and non-HDL-C is not settled, and it is still largely a research-grade tool. ApoB gives you most of the same information with cleaner standardization, so reach for ApoB first and treat particle subfractionation as supplementary, not foundational.
When this workup is warranted
Not on everyone. It earns its place in the patient with insulin resistance or a rising triglyceride to HDL ratio, a family history of early cardiovascular disease, a personal or family history that does not match a normal standard panel, or metabolic syndrome features where you suspect the standard lipid numbers are understating the true risk.
The functional takeaway
The standard lipid panel is the starting point, not the finish line. When the metabolic picture or the family history says the risk is greater than the cholesterol numbers suggest, ApoB counts the particles the standard panel cannot see, Lp(a) explains the genetic risk it cannot account for, and hs-CRP tells you whether that burden is meeting an inflamed artery. Ordered when the story warrants it, this workup catches the cardiovascular risk that hides behind a normal-looking panel.
Written by Dr. Sheri Erwin, DNP, APRN, FNP-C
Founder, BridgeWell Integrative Education. 30+ years in healthcare, 16+ years training nurse practitioners. Systems-based, CE-accredited, and designed for NP scope from the ground up.
This Is What BridgeWell Clinical Depth Looks Like in Every Course.
Every BridgeWell course is built on the systems-based reasoning you just read about, applied to real patients and designed for NP scope.